Empagliflozin/metformin

From Wikipedia, the free encyclopedia
(Redirected from Synjardy)
Jump to navigation Jump to search

Empagliflozin/metformin
Combination of
EmpagliflozinSGLT2 inhibitor
Metformin HydrochlorideAnti-diabetic biguanide
Clinical data
Trade namesSynjardy, Jardiamet
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
PubChem CID
KEGG
ChEBI
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H39Cl2N5O7
Molar mass616.54 g·mol−1
3D model (JSmol)
  • CN(C)C(=N)N=C(N)N.COC1C(C(C(C(O1)C2=CC(=C(C=C2)Cl)CC3=CC=C(C=C3)OC4CCOC4)O)O)O.Cl
  • InChI=1S/C23H27ClO7.C4H11N5.ClH/c1-28-23-21(27)19(25)20(26)22(31-23)14-4-7-18(24)15(11-14)10-13-2-5-16(6-3-13)30-17-8-9-29-12-17;1-9(2)4(7)8-3(5)6;/h2-7,11,17,19-23,25-27H,8-10,12H2,1H3;1-2H3,(H5,5,6,7,8);1H/t17-,19+,20+,21-,22-,23-;;/m0../s1
  • Key:YBRWIMHXUHRVDV-ZBYKXHQASA-N

Empagliflozin/metformin, sold under the brand name Synjardy among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[7][8] It contains empagliflozin and metformin hydrochloride.[5][6] It is taken by mouth.[5][6]

The most common side effects include hypoglycaemia (low blood sugar levels) when the medicine is taken with a sulphonylurea or insulin, infections of the urinary tract and genitals, and increased urination.[6]

It was approved for use in the European Union in May 2015,[6] for use in the United States in August 2015,[9] and for use in Australia in May 2020.[2] In 2020, it was the 238th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[10][11] It is available as a generic medication.[12]

Medical uses

[edit | edit source]

In the European Union empagliflozin/metformin is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control:[6]

  • in adults inadequately controlled on their maximally tolerated dose of metformin alone;[6]
  • in adults inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;[6]
  • in adults already being treated with the combination of empagliflozin and metformin as separate tablets.[6]

In the United States it is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.[5]

In June 2023, the US Food and Drug Administration (FDA) expanded the indication, as an addition to diet and exercise, to improve blood sugar control in children 10 years and older with type 2 diabetes.[13]

Society and culture

[edit | edit source]
[edit | edit source]

Empagliflozin/metformin was approved for use in the European Union in May 2015.[6]

Empagliflozin/metformin was approved for use in the United States in August 2015.[9][14] The extended release version was approved for use in the United States in December 2016.[15][16]

Empagliflozin/metformin was approved for use in Australia in May 2020.[2]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).[permanent dead link]
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ a b c d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  6. ^ a b c d e f g h i j Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value). Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  8. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  9. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  10. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  11. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  12. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  13. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).[dead link]
  14. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  15. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).[dead link]
  16. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

Lua error in mw.title.lua at line 392: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in Module:Authority_control at line 153: attempt to index field 'wikibase' (a nil value).

Retrieved from "http://70.231.62.181/index.php?title=Empagliflozin/metformin&oldid=21979597"